language:english – DEARGEN UPDATES

2020년 3월 23일2020년 6월 18일

Five Companies Using AI to Fight Coronavirus

Deep learning models predict old and new drugs that might successfully treat COVID-19.

2020년 2월 7일2020년 6월 18일

Deargen Predicted Potential Antivirals for The Novel Coronavirus Infection using AI

Deargen, predicted a drug with high potential for treatment of a new coronavirus (2019-nCoV) using the deep-learning technology based AI model MT-DTI. The work is published on the BioRxiv.

2020년 2월 5일2020년 6월 17일

MolEQ, an artificial intelligence model that adjusts multiple property at the same time and optimizes small-molecule lead compounds

Deargen Presented a self-developed small-molecule lead optimization model, MolEQ (Molecule Equalizer) at the Advancing Precision Medicine Drug Development : Incorporation of Real-World Data and Other Novel Strategies Special Conference which was held from AACR on January 9 – 12.

2019년 9월 3일2020년 6월 17일

First-in Class Drug Targeting DDT2 (Code Name) Transcription Factor for Primary Cancers

We introduce the process of finding key targets for primary cancers using our AI technologies such as Wx and DearTRANS.

2019년 8월 14일2020년 6월 17일

A new state of the art drug target interaction model, Molecule Transformer based Drug Target Interaction (MT-DTI) Model.

Deargen Presented a world-class drug-protein interaction prediction model, MT-DTI (Molecule Transformer Drug Target Interaction Model). This research is published in the Journal of Machine Learning Research (JMLR).

2019년 8월 12일2020년 6월 17일

[Press Release] Deargen, Unveil the performance Results of a New Drug-Protein Interaction Prediction Model.

Deargen Inc. Presented at MLHC 2019, “All 8 FDA-approved EGFR anticancer drugs were predicted using a database of ninety-seven million chemical compounds”.

2019년 8월 5일2020년 6월 17일

Treatment of Sarcopenia using Small Molecules

Sarcopenia is a new type of age-related disease that has been newly classified as a disease since October 2016. It is defined as a disease with a reduction in skeletal muscle mass as aging progresses and there are no treatments for age-related sarcopenia that have been approved by the FDA so far. In this regard, Deargen is challenging the development of treatments for sarcopenia using small molecules.

2019년 8월 5일2020년 6월 17일

Undruggable to Degradable with AI

PROTAC is known as a new platform for disease treatment that has been difficult to reach with existing biopharmaceuticals. Deargen is accelerating the development of drugs through PROTAC by rapidly and precisely searching for small molecules that can bind to the target protein.

2019년 8월 5일2020년 6월 17일

Colorectal Cancer, MERTK, and Small molecular

The study of colorectal cancer has shown that MERTK (TYRO3 / AXL / MER, TAM receptor kinase family) is an important target for cancer cell immune response evasion mechanism. Thus, Deargen is researching by focusing on small molecule inhibitors.

2019년 8월 5일2020년 6월 17일

ALS (Lou Gehrig), a Challenge to Radical Cure

ALS treatments that currently are being used under FDA approval have a level that relieves symptoms and slows the progression of Lou Gehrig. Deargen is challenging the development of new ALS treatments by reducing TDP-43 protein aggregation observed in more than 90% of patients with Lou Gehrig.